This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Harold C. Pillsbury, III, MD; William P. Webster, DDS; Julian Rosenman, MD

Arch Otolaryngol Head Neck Surg. 1986;112(5):552-553.

Abstract
• Radiotherapy is the usual mode of treatment for unresectable head and neck cancer. To improve cure rates, extend survival, and reduce morbidity, we use accelerated hyperfractionation radiotherapy and an adjuvant drug to inhibit prostaglandin synthesis. In this study, 19 patients received 300 rad/day of radiotherapy in two equally divided doses to a total dose averaging 6,200 rad. Either indomethacin, 25 mg, or placebo was given four times a day in a double-blind fashion during therapy. Radiation mucositis was graded as 0 to 4+; pain, nutritional status, and tumor status were monitored daily and recorded biweekly. Evaluation of the data showed delayed mucositis in the experimental group for grades 1 to 3, with a significant difference at grade 3 compared with controls. The significance of a long-term comparison of cure rates would be doubtful considering the heterogeneity of the primary sites and regional disease in this group coupled with the small size of our study.

(Arch Otolaryngol Head Neck Surg 1986;112:552-553)

Author Affiliations
From the Schools of Medicine (Drs Pillsbury and Rosenman) and Dentistry (Dr Webster), University of North Carolina, Chapel Hill.

Footnotes
Accepted for publication Sept 6, 1985.

Read before the American Society for Head and Neck Surgery, Dorado Beach, Puerto Rico, May 7, 1985.

Reprint requests to Division of Otolaryngology, 610 Burnett-Womack Bldg 229H, University of North Carolina, Chapel Hill, NC 27514 (Dr Pillsbury).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Preventive Intervention Possibilities in Radiotherapy- and Chemotherapy-induced Oral Mucositis: Results of Meta-analyses
Stokman et al.
JDR 2006;85:690-700.
ABSTRACT | FULL TEXT  

Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?
Choy and Milas
JNCI J Natl Cancer Inst 2003;95:1440-1452.
ABSTRACT | FULL TEXT  

Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment
Kostler et al.
CA Cancer J Clin 2001;51:290-315.
ABSTRACT | FULL TEXT